Manufacturer
SANOFI PASTEUR
Contents
Diphtheria toxoid not <20 IU; tetanus toxoid not <40 IU; Bordetella pertussis antigens: Pertusis toxoid 25 mcg, filamentous haemagglutinin 25 mcg; inactivated poliovirus: type 1 (Mahoney) 40 D antigen units, type 2 (MEF-1) 8 D antigen units, type 3 (Saukett) 32 D antigen units; HBsAg 10 mcg; H influenzae type b (HIB) polysaccharide 12 mcg (polyribosylribitol phosphate) conjugated to tetanus protein 22-36 mcg
Indication
Primary & booster vaccination of infants & toddlers from 6 wk-24 mth against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis & invasive diseases caused by HIB.
Instruction
Administer via IM injection.
Drug interaction
Data on concomitant administration of Hexaxim with a pneumococcal polysaccharide conjugated vaccine have shown no clinically relevant interference in the antibody response to each of the antigens.
Data on concomitant administration of a booster dose of Hexaxim with measles-mumps-rubella vaccines have shown no clinically relevant interference in the antibody response to each of the antigens. There may be a clinically relevant interference in the antibody response of Hexaxim and a varicella vaccine and these vaccines should not be administered at the same time. Data on concomitant administration of rotavirus vaccines have shown no clinically relevant interference in the antibody response to each of the antigens. Data on concomitant administration of Hexaxim with a meningococcal C conjugate vaccine or a meningococcal group A, C, W-135 and Y conjugate vaccine have shown no clinically relevant interference in the antibody response to each of the antigens. If co-administration with another vaccine is considered, immunisation should be carried out on separate injections sites. Hexaxim must not be mixed with any other vaccines or other parenterally administered medicinal products. No significant clinical interaction with other treatments or biological products has been reported except in the case of immunosuppressive therapy.
SANOFI PASTEUR
Contents
Diphtheria toxoid not <20 IU; tetanus toxoid not <40 IU; Bordetella pertussis antigens: Pertusis toxoid 25 mcg, filamentous haemagglutinin 25 mcg; inactivated poliovirus: type 1 (Mahoney) 40 D antigen units, type 2 (MEF-1) 8 D antigen units, type 3 (Saukett) 32 D antigen units; HBsAg 10 mcg; H influenzae type b (HIB) polysaccharide 12 mcg (polyribosylribitol phosphate) conjugated to tetanus protein 22-36 mcg
Indication
Primary & booster vaccination of infants & toddlers from 6 wk-24 mth against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis & invasive diseases caused by HIB.
Instruction
Administer via IM injection.
Drug interaction
Data on concomitant administration of Hexaxim with a pneumococcal polysaccharide conjugated vaccine have shown no clinically relevant interference in the antibody response to each of the antigens.
Data on concomitant administration of a booster dose of Hexaxim with measles-mumps-rubella vaccines have shown no clinically relevant interference in the antibody response to each of the antigens. There may be a clinically relevant interference in the antibody response of Hexaxim and a varicella vaccine and these vaccines should not be administered at the same time. Data on concomitant administration of rotavirus vaccines have shown no clinically relevant interference in the antibody response to each of the antigens. Data on concomitant administration of Hexaxim with a meningococcal C conjugate vaccine or a meningococcal group A, C, W-135 and Y conjugate vaccine have shown no clinically relevant interference in the antibody response to each of the antigens. If co-administration with another vaccine is considered, immunisation should be carried out on separate injections sites. Hexaxim must not be mixed with any other vaccines or other parenterally administered medicinal products. No significant clinical interaction with other treatments or biological products has been reported except in the case of immunosuppressive therapy.
Inquiry - Hexaxim Suspension for Injection